Monitoring the rates of composite events with censored data in phase II clinical trials.

Monitoring the rates of composite events with censored data in phase II clinical trials.

Item
http://www.wikidata.org/entity/Q30679019
Design of Phase II cancer trials evaluating survival probabilitiesSuspension of accrual in phase II cancer clinical trials.A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation.Risk-group-specific dose finding based on an average toxicity score.Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma.Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization.Bayesian decision theoretic two-stage design in phase II clinical trials with survival endpointTime-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial.New pathways for evaluating potential acute stroke therapies.A Bayesian dose-finding design for drug combination clinical trials based on the logistic model.Adaptive randomization for multiarm comparative clinical trials based on joint efficacy/toxicity outcomes.Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.Monitoring event times in early phase clinical trials: some practical issues.Ethical issues in oncology biostatistics.
P2860

Monitoring the rates of composite events with censored data in phase II clinical trials.

Item
http://www.wikidata.org/entity/Q30679019
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Monitoring the rates of composite events with censored data in phase II clinical trials.
@ast
Monitoring the rates of composite events with censored data in phase II clinical trials.
@en
type
label
Monitoring the rates of composite events with censored data in phase II clinical trials.
@ast
Monitoring the rates of composite events with censored data in phase II clinical trials.
@en
prefLabel
Monitoring the rates of composite events with censored data in phase II clinical trials.
@ast
Monitoring the rates of composite events with censored data in phase II clinical trials.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P356
P1433
P1476
Monitoring the rates of composite events with censored data in phase II clinical trials.
@en
P2093
P2860
P304
P31
P356
10.1111/J.0006-341X.2002.00089.X
P407
P433
P478
P577
P698
P921